SEC Form SC 13G filed by Arcus Biosciences Inc.
$RCUS
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/21/2024 | $20.00 | Neutral | H.C. Wainwright |
| 10/8/2024 | $29.00 | Overweight | Wells Fargo |
| 11/18/2022 | $33.00 | Neutral | BofA Securities |
| 10/11/2022 | $40.00 | Overweight | Morgan Stanley |
| 11/19/2021 | $42.00 → $53.00 | Buy | Citigroup |
| 11/19/2021 | $48.00 → $60.00 | Overweight | Barclays |
| 11/18/2021 | $68.00 → $100.00 | Outperform | SVB Leerink |
| 11/9/2021 | $45.00 → $48.00 | Overweight | Barclays |
Data from the Phase 1/1b ARC-20 study of casdatifan were presented at an oral plenary session at the 2024 EORTC-NCI-AACR Symposium; a low rate of primary progression (19%) and promising objective response rate (34% with 2 responses pending confirmation, 25% confirmed) for the 100mg daily (50mg twice-daily) cohort of heavily pretreated patients with clear-cell renal cell carcinoma (ccRCC) support a potential best-in-class profile Arcus announced a clinical trial collaboration agreement with AstraZeneca to evaluate casdatifan in combination with volrustomig, an investigational PD-1/CTLA-4 bispecific antibody, in patients with immuno-oncology (IO)-naive ccRCC Data from the randomized ARC-
Domvanalimab plus zimberelimab was associated with greater progression-free survival, overall survival, and objective response rate compared with those of zimberelimab or chemotherapy A 36% reduction in risk of death (HR=0.64) was observed for domvanalimab plus zimberelimab compared to zimberelimab alone; zimberelimab reached a median overall survival of two years while the median overall survival for domvanalimab plus zimberelimab was not reached Treatment-related adverse events leading to treatment discontinuation were low (10.5%) for the combination of domvanalimab and zimberelimab relative to chemotherapy (23.5%) Arcus will discuss these results on its earnings call at 2:00 PM
Objective response rate of 34% (2 responses pending confirmation) and 25% (confirmed) in the 100mg daily dose expansion cohort (n=32) of ARC-20, a Phase 1/1b study of casdatifan in metastatic clear cell renal cell carcinoma (ccRCC) Low rate of primary progression (19%) and high rate of disease control (81%) was observed in the 100mg expansion cohort with many of those patients still on treatment Arcus will host a conference call to discuss these results, including results from the 50mg expansion cohort, at 5:00 AM PT / 8:00 AM ET today Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combinati
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in December: Evercore 7th Annual HealthCONx Conference Date: Tuesday, December 3rd, 2024 Location: Coral Gables, FL Format: Fireside chat & 1x1 meetings Time: 7:55 a.m. ET Citi 2024 Global Healthcare Conference Date: Wednesday, December 4th, 2024 Location: Miami, FL Format: 1x1 meetings only Live webcasts of the fireside chats and panel will be available by visiting the "Investors & Media" section of the Arcus
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted four new employees options to purchase a total of 14,100 shares of the Company's common stock at an exercise price per share of $17.85, which was the closing price on November 8, 2024, and restricted stock units to acquire a total of 7,050 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January
Data from the Phase 1/1b ARC-20 study of casdatifan were presented at an oral plenary session at the 2024 EORTC-NCI-AACR Symposium; a low rate of primary progression (19%) and promising objective response rate (34% with 2 responses pending confirmation, 25% confirmed) for the 100mg daily (50mg twice-daily) cohort of heavily pretreated patients with clear-cell renal cell carcinoma (ccRCC) support a potential best-in-class profile Arcus announced a clinical trial collaboration agreement with AstraZeneca to evaluate casdatifan in combination with volrustomig, an investigational PD-1/CTLA-4 bispecific antibody, in patients with immuno-oncology (IO)-naive ccRCC Data from the randomized ARC-
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that, in connection with the appointment of the Company's new Chief Medical Officer, Dimitry S.A. Nuyten, M.D., Ph.D, the Compensation Committee of the Company's Board of Directors granted Dr. Nuyten an option to purchase 170,000 shares of the Company's common stock at an exercise price per share of $26.00, which was the closing price on August 23, 2022, and restricted stock units to acquire a total of 42,500 shares of the Company's common stock. In addition to the awards to Dr. Nuyten, the Compensation Committee granted fifteen other new emplo
Dr. Nuyten will oversee Arcus's clinical development organization that includes nearly 200 employees and six clinical-stage programs targeting TIGIT, the adenosine axis (CD73 and dual A2a/A2b), HIF-2a and PD-1 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that Dimitry S.A. Nuyten, M.D., Ph.D has been appointed chief medical officer (CMO) effective August 1, 2022. In his role as CMO, Dr. Nuyten will oversee Arcus's clinical development organization that includes nearly 200 employees and six clinical-stage programs targeting TIGIT, the a
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 31,600 shares of the Company’s common stock at an exercise price per share of $30.83, which was the closing price on January 8, 2021. The stock options were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08. About Arcu
H.C. Wainwright initiated coverage of Arcus Biosciences with a rating of Neutral and set a new price target of $20.00
Wells Fargo initiated coverage of Arcus Biosciences with a rating of Overweight and set a new price target of $29.00
BofA Securities initiated coverage of Arcus Biosciences with a rating of Neutral and set a new price target of $33.00
10-Q - Arcus Biosciences, Inc. (0001724521) (Filer)
8-K - Arcus Biosciences, Inc. (0001724521) (Filer)
8-K - Arcus Biosciences, Inc. (0001724521) (Filer)
This option exercise is based on an option and license agreement between Taiho and Arcus contracted in September 2017. This is the fourth option exercise by Taiho to an Arcus program. In exchange for the exclusive license of quemliclustat, Taiho will make an option exercise payment, as well as additional payments upon achievement of clinical, regulatory and commercialization milestones, and, if any products from the program are approved, will pay royalties on net sales of such products.
Arcus Biosciences (NYSE:RCUS) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 0 1 0 0 0 1M Ago 1 0 0 0 0 2M Ago 1 1 0 0 0 3M Ago 0 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Arcus Biosciences, presenting an average target of $34.25, a high estimate of $44.00, and a low estimate of $25.00. Observing a downward
Barclays analyst Peter Lawson maintains Arcus Biosciences (NYSE:RCUS) with a Overweight and lowers the price target from $35 to $25.
SC 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)
SC 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)
SC 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)
4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
4 - Arcus Biosciences, Inc. (0001724521) (Issuer)